Ireland has the potential to expand its presence in the global cannabinoid medicines market by leveraging its established pharmaceutical manufacturing expertise, regulatory capabilities and growing scientific research base, according to industry representatives.

Speaking in an interview with Silicon Republic, Dunbar Pharma co-founder and chief executive Leah Fletcher highlighted Ireland's strengths in pharmaceutical manufacturing, quality systems and compliance, suggesting these capabilities could support future growth in cannabinoid-based therapies and related pharmaceutical products.

Cannabinoid medicines are increasingly attracting attention worldwide as researchers and healthcare providers explore their potential use in managing a range of medical conditions. While access to such therapies in Ireland remains limited and highly regulated, Fletcher noted that the country's pharmaceutical infrastructure places it in a strong position to participate in the sector's development.

Ireland is already home to a significant concentration of pharmaceutical manufacturing facilities and life sciences expertise. Fletcher also pointed to ongoing academic research in cannabinoid science at Irish institutions, including the University of Galway and Trinity College Dublin, as evidence of a growing knowledge base that could support innovation in the field.

The discussion also highlighted challenges facing pharmaceutical start-ups operating within highly regulated environments. According to Fletcher, companies developing medicines often require substantial investment in areas such as licensing, facility development, validation programmes, specialist equipment and skilled personnel before reaching commercial scale.

She argued that funding structures designed specifically for regulated life sciences businesses could help more indigenous pharmaceutical companies grow internationally. Such support could be particularly important for companies developing innovative therapies, where development timelines are typically longer and regulatory requirements more extensive than in many other industries.

As global interest in alternative and specialised therapies continues to evolve, Ireland's combination of manufacturing expertise, regulatory oversight and scientific capability may provide opportunities for further growth in cannabinoid medicine development. Industry stakeholders believe that continued investment and collaboration could help strengthen the country's role in this emerging area of pharmaceutical innovation.

Explore the full interview and industry insights at the original source.